Alvotech (Nasdaq: ALVO) has signed a licensing and commercialisation agreement with Lotus Pharmaceutical covering two proposed biosimilars in the United States and eight Asian markets, with potential upfront and milestone payments to Alvotech of up to approximately $150 million plus future product-supply revenue. The agreement covers AVT34, a proposed biosimilar to AstraZeneca’s durvalumab product Imfinzi, and AVT87, a proposed biosimilar to Roche’s emicizumab product Hemlibra.
The commercial opportunity is substantial, although the reference-product sales figures should not be confused with revenue available to the biosimilar partners. Imfinzi generated approximately $6.1 billion in global sales in 2025, while Hemlibra produced around CHF4.8 billion, or approximately $5.8 billion, giving the two reference medicines combined global sales of roughly $11.9 billion.
Alvotech shares closed around $4.43 on August 21 and were higher on the session, while recent market data placed the company’s market capitalisation at approximately $1.5 billion. The stock remained down almost 48% over 12 months despite a stronger recent recovery, leaving investors highly sensitive to pipeline, liquidity and commercialisation developments.
How does the $150 million Lotus agreement actually work?
The maximum approximately $150 million consists of upfront and milestone payments rather than guaranteed cash received at signing. Individual milestones were not disclosed in the announcement, so investors cannot yet determine how much is payable immediately, how much depends on development or regulatory events and how much may require successful commercialisation.
Alvotech will also generate ongoing revenue as exclusive supplier of both products across the covered territories. This supply component could become economically important if the biosimilars gain approval and meaningful market share, but no sales value has been guaranteed.
The structure therefore contains two potential revenue streams: contractual payments linked to specified milestones and longer-term product supply. Treating the entire $150 million as immediate revenue would materially overstate the current economics.
Why is Alvotech retaining direct US commercialisation rights?
The United States agreement is semi-exclusive. Lotus will commercialise through its wholly owned US subsidiary Alvogen, but Alvotech retains the right to commercialise both products directly alongside Lotus. Alvotech also remains responsible for development and for obtaining and maintaining US marketing authorisations.
That arrangement marks an evolution in Alvotech’s commercial strategy because it retains more direct participation in the US economics rather than simply licensing all commercial rights to a partner. The upside is potentially greater value capture if the products succeed; the trade-off is greater commercial responsibility.
In Asia, the structure is different. Lotus receives exclusive commercial rights in South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia and will handle local regulatory submissions and commercialisation.
How meaningful is the $150 million potential value for Alvotech’s finances?
Alvotech reported adjusted first-half 2026 revenue of $211.9 million, down from $306.1 million a year earlier, while adjusted EBITDA declined to $46.9 million from $53.7 million. Cash at June 30 stood at $142.8 million compared with $172.4 million at the end of 2025.
Against those figures, the maximum $150 million of upfront and milestone consideration is equivalent to about 71% of first-half adjusted revenue and slightly exceeds the June cash balance. That comparison demonstrates potential financial significance, but timing remains crucial because the full contractual amount is conditional.
Alvotech has also been strengthening liquidity through financing transactions, meaning non-dilutive or commercially linked milestone receipts could help reduce dependence on additional capital if development progresses as planned.
What must happen before AVT34 and AVT87 can generate commercial sales?
Both medicines remain proposed biosimilars rather than approved substitutes in the territories covered by the agreement. Alvotech must complete development programmes capable of demonstrating biosimilarity to the reference products and obtain applicable regulatory approvals before commercial launches can begin.
That qualification matters particularly because the approximately $11.9 billion reference-product sales opportunity may look enormous compared with Alvotech’s current revenue. Biosimilars generally compete at lower prices than originator biologics, frequently face multiple competitors and do not automatically capture large portions of the underlying reference market.
The commercial opportunity is still significant because oncology and haemophilia biologics are high-value categories where biosimilar competition can open substantial markets. The Lotus agreement provides Alvotech with a partner network across Asia while preserving direct US participation.
Why did Alvotech shares respond positively to the Lotus agreement?
Alvotech’s latest market data showed the shares closing at approximately $4.43 on August 21, with the licensing news associated with a positive session after the stock had also gained following its first-half results. The shares remained far below their $9.25 52-week high, demonstrating that investors still price considerable execution and financing risk into the company.
The Lotus announcement addresses one element of that risk by establishing commercial partners and potential milestone economics before the candidates reach the market. It also gives Alvotech direct US commercial rights, potentially raising its share of future value if the products succeed.
The agreement does not remove clinical, regulatory or competitive uncertainty. What it does is attach a clearer commercial framework to two pipeline assets addressing reference medicines with almost $12 billion of combined annual global sales. For a company with first-half adjusted revenue of about $212 million, that makes AVT34 and AVT87 strategically important even though most of their potential economic contribution still lies ahead.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
